In animal studies, typically involving rats and mice, doses range from 0.1 to 10 micrograms per kilogram of body weight, administered via intramuscular, subcutaneous, or oral routes
Our weight-loss program is designed to be safe, supportive, and effective
The increase in post-prandial insulin and reduction in glucagon can also lower nonesterified fatty acids and inhibit adipose tissue lipolysis (48,49), further improving lipid profiles
These include slower dose escalation schedules (microdosing protocols starting at 0.25 mg or lower weekly increments), consistent meal timing, avoiding high-fat foods during dose adjustment periods, and co-prescribing antiemetics temporarily if needed